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ABSTRACT 
Background: Tobacco use is a major public health concern, and is associated with a number of 
mental illnesses as well as increased alcohol/other drug (AOD). Research into treatment for 
individuals experiencing such comorbidities is limited.  
Design and Methods: Participants (n=447) were those enrolled in the Depression and Alcohol 
Integrated and Single-focused Interventions project (Baker et al., 2010), and the Self Help for 
Alcohol/other drugs and DEpression project (Kay-Lambkin, Baker, Kelly, & Lewin, 2011), who 
reported current depression and hazardous alcohol use at entry to the study.  Smoking 
cessation was not targeted in, nor a goal of, treatment. 
Results: After controlling for socioeconomic variables, tobacco use was not associated with 
higher levels of depressive symptoms at baseline; however heavy smokers (30+ cigarettes per 
day) consumed significantly more alcohol at baseline than did non-smokers (13 vs. 9 standard 
drinks per day).  Baseline smoking severity did not impact on depression or alcohol use 
outcomes over a 12-month period.  Reductions in tobacco use between baseline and 3-month 
follow-up were significantly associated with reductions in depression and alcohol consumption 
over the same time period. 
Discussion and Conclusions: The study results suggest that tobacco use does not interfere with 
treatment for depression and alcohol use problems, and adds weight to the idea of considering 
specific treatment for tobacco use in the context of treatment for alcohol/other drug use.  
Keywords: tobacco, depression, alcohol-related disorders, therapy 
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INTRODUCTION 
In the most recent survey into alcohol/other drug (AOD) use conducted by the Australian 
Institute of Health and Welfare, 19.4% of adults were current smokers, with 16.6% reporting 
regular daily tobacco smoking (AIHW, 2008).  Younger Australians are significantly more likely 
to smoke tobacco, with peak tobacco smoking occurring in the 20-29 years age group, and 
males for the most part reporting the highest rates of daily smoking across the lifespan (AIHW, 
2008).  Smoking is also associated with socioeconomic status, with those from disadvantaged 
backgrounds being more likely to smoke, and additional links are found between smoking and 
geographical region as well as country of birth.  People with mental health and AOD use 
problems are also among those groups reporting significantly higher rates of tobacco smoking 
than the general population (A. L. Baker et al., 2006). 
 
Depression and smoking 
In particular, the association between depression and cigarette smoking is of concern.  Aside 
from the increased cardiovascular risk associated with both depression and tobacco smoking, 
compared to non-smokers, regular smokers report more frequent and severe episodes of 
depression, and higher suicide ideation and rates of suicide (K. Wilhelm, Wedgewood, Niven, & 
Kay-Lambkin, 2006).  Smoking remains one of the strongest correlates of current Major 
Depressive Disorder (K.  Wilhelm, Mitchell, Slade, Brownhill, & Andrews, 2003).  Rates and 
severity of nicotine dependence are higher amongst those with depression, and negative 
affect is the most commonly cited reason for unsuccessful smoking cessation attempts (K. 
Wilhelm et al., 2006). 
 
Alcohol and other drug use and smoking 
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AOD use has also been suggested to occur at higher rates in smokers than non-smokers 
(Cargill, Emmons, Kahler, & Brown, 2001).  Over one-fifth of current smokers in Australia 
report concurrent risky consumption of alcohol, compared with 16% of ex-smokers and 8% of 
never smokers (ABS, 2006).  There is some suggestion that tobacco smoking among AOD 
treatment populations is as high as 100%, with a strong relationship observed between 
tobacco smoking and other substance use such as cannabis, heroin and cocaine (A. L. Baker et 
al., 2006).   
 
The extent of the connection between tobacco smoking and alcohol dependence is of 
particular note, with reports in the USA of over 80% of adolescents being treated for alcohol 
use disorders also smoking tobacco (K. Shelef, G. Diamond, G. Diamond, & M. Myers, 2009a). 
This is in comparison to approximately 25% in the general US population who report tobacco 
smoking alone (Dunn et al., 2010).  Nicotine dependence is also more severe in individuals who 
drink alcohol as opposed to those who are abstinent (Cooney et al., 2007), and smoking among 
people who are dependent on alcohol has been shown to be associated with deaths than 
alcohol consumption alone (Hitsman et al., 2002). 
  
Comorbid smoking, depression and alcohol misuse 
At present, there is only a modest understanding of the interaction between depression, 
alcohol and tobacco smoking, and even less on what an appropriate treatment for this 
particular type of comorbidity might comprise (Jane-Llopis & Matytsina, 2006).  
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There are, however, potential difficulties in examining these issues in real world settings.  For 
example, in psychiatric and AOD treatment settings, smoking tobacco is often viewed as a 
lesser evil and is ignored, perhaps at times encouraged (A. L. Baker et al., 2006), particularly in 
the context of poly-substance use treatment programs (Kalman, Kim, DiGirolamo, Smelson, & 
Ziedoni, 2010).  Other concerns include the fear that a quit attempt might result in poorer 
mental health or AOD treatment outcomes.  However, research now suggests that between 
46-80% of participants in drug treatment wish to quit smoking (A. Baker et al., 2006). Other 
studies suggest that making a quit attempt in alcohol treatment did not negatively impact on 
treatment outcome (Kahler et al., 2008). 
 
Given the limited understanding of the comorbidities of depression, alcohol and tobacco use, 
effective treatment for this subgroup remains a cloudy issue. Evidence based treatment for 
depression has been well documented (APA, 2000), as has treatment for substance use (APA, 
1995), and smoking cessation (APA, 1996), with cognitive behavior therapy being a treatment 
of choice for each of these conditions occurring in isolation.  Despite this, little evidence exists 
to suggest how well these treatment strategies generalize to people experiencing these 
conditions as they co-occur.  
 
Comorbidity research conducted with other co-occurring disorders has investigated the 
changes in a secondary disorder following treatment targeting a primary disorder, exploring 
the generalisability of the treatment modalities utilized.  For example, CBT and other 
treatment strategies such as enhancing motivation, identifying triggers, learning refusal skills, 
and improving emotional coping skills, are areas of common ground in the treatment of 
substance use disorders and tobacco use (Shelef et al., 2009a). A sense of achievement in the 
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reduction of one substance may also have a carryover effect in the reduction in the use of a 
secondary substance (Shelef et al., 2009a).  While promising, the ability of people with 
comorbidity to generalize skills learned in treatment to other behaviors and issues not 
targeted in that treatment program has not yet been tested (Alati et al., 2004; K. Shelef, G. S. 
Diamond, G. M. Diamond, & M. Myers, 2009b). The current study has been designed to 
address this gap. 
 
The current study 
We have previously conducted two randomized controlled trials (Baker et al., 2010; Kay-
Lambkin, Baker, Kelly, et al., 2011) comparing brief (1-session advice and motivational 
interviewing, MI) and extended (10 sessions MI/cognitive behavior therapy, CBT) interventions 
for comorbid depression and AOD use problems; the first large-scale randomized controlled 
trials of CBT for comorbid depression and AOD use problems.  These studies also present the 
opportunity to explore the prevalence of smoking amongst this important comorbid 
population, and examine the impact on smoking, if any, of CBT-focused treatments for 
depression and AOD use problems, and vice versa.  The present paper reports findings from a 
combination of datasets from these studies for people who met study entry criteria for at least 
hazardous use of alcohol and moderate depressive symptomatology.  Specifically, it is 
hypothesized that: 
(a) At baseline, heavy smokers will report higher levels of depression and alcohol use than 
will non-smokers;  
(b) Heavy smokers will have poorer outcomes on measures of depression and alcohol use 
than non-smokers; and  
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(c) Significant reductions in smoking tobacco will be observed from pre- to post-treatment 
and that these reductions will be moderated by treatment condition.   
 
METHODS 
Participants 
Participants were those enrolled in the Depression and Alcohol Integrated and Single-focused 
Interventions project (DAISI, Baker et al., 2010), and the Self Help for Alcohol/other drugs and 
DEpression project (SHADE, Kay-Lambkin, Baker, Kelly, et al., 2011), which commenced in 2006 
and 2005 respectively.  To be included in the current study, eligible participants were those 
with current depressive symptoms (≥ 17 on the Beck Depression Inventory II, BDI-II, Beck, 
Steer, & Brown, 1996) and concurrent use of alcohol in excess of recommended national 
guidelines in Australia at the time of the study (NHMRC, 2009), which equated to consumption 
above an average of four 10gm ethanol drinks per day for men, or two per day for women.  
Individuals who exhibited psychotic symptoms, those requiring medical detoxification, who 
had learning difficulties, were non-English speaking or who had organic brain disease at 
baseline were excluded.  Participants could be using a range of other drugs, including tobacco, 
at entry to the study.   
 
Assessment Measures 
All assessment measures are widely used in mental health and AOD clinical and research 
settings, and were common to both the SHADE and DAISI projects and to all assessment 
timepoints.  The assessments included: 
(a) Demographics and treatment history: including age, gender, employment and education 
status.  
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(b) Temporal primacy of depression or alcohol use disorder (primacy): a timeline of depressive 
symptoms and alcohol consumption over the person’s lifetime was completed to determine 
whether the person’s first occurrence of symptoms of depression were prior or subsequent 
to the onset of regular alcohol use. 
(c) Structured Clinical Interview for DSM-IV, Research Version (SCID-RV, First, 2001): provided 
a diagnostic, clinician-rated measure of depression and alcohol abuse and dependence. 
(d) BDI-II (Beck et al., 1996): a 21-item self-report questionnaire used to screen for the 
presence of depressive symptoms over the previous two-week period. 
(e) Opiate Treatment Index (OTI, Darke, Hall, Wodak, Heather, & Ward, 1992): addresses the 
quantity and frequency of AOD use over the month prior to assessment, three of which are 
relevant to the current study; alcohol, cannabis and cigarette use.  For tobacco smoking, 
participants recalled their three most recent tobacco-smoking occasions, and estimated the 
number of cigarettes smoked on each of those occasions.  A score was calculated based on 
these reports, summarizing the quantity and frequency of tobacco smoking for those use 
occasions falling in the same month prior to baseline.  Each occasion of use equated to one 
day, and so the resultant score is essentially equivalent to cigarettes per day. 
(f) Global Assessment of Functioning Scale (GAF, APA, 1994):  provides an index of overall 
functioning incorporating the domains of psychological, social and occupational status.  
(g) Brief Symptom Inventory (BSI, Derogatis & Melisaratos, 1983): is a self-report measure of 
psychopathology and general stress. The following domains of distress were included: 
somatization, anxiety, and phobic anxiety.  
 
Procedures 
Detailed description of the study procedures have been published for the SHADE (Kay-
Lambkin, Baker, Kelly, et al., 2011) and DAISI (Baker et al., 2010) studies elsewhere.  For both 
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studies, following the provision of informed consent, eligible participants completed a baseline 
clinical interview with a Registered or Intern Psychologist, usually over two one-hour sessions, 
one week apart.  All participants then received an initial session comprising advice and MI 
focused on depression and alcohol misuse, conducted face-to-face with a Registered or Intern 
Psychologist.  At the conclusion of this session, participants were randomized into no further 
treatment (Brief Intervention (BI) condition), or conditions that ensued over the following 9 
weeks.  Regardless of treatment attendance, all participants were eligible for follow-up 
assessment, which occurred at 3-, 6-, and 12-months post-baseline, and were conducted by a 
blind assessor independent from the treatment phase of the projects.   
 
The DAISI project employed four psychological treatment programs of combination MI and 
CBT that were conducted face-to-face with trained Psychologists: 
(a) 1 60-minute integrated BI that addressed depression and alcohol use concurrently; 
(b) 10 60-minute sessions of MI/CBT that targeted alcohol use, including the BI as session 1 
(Alc); 
(c) 10 60-minute sessions of MI/CBT that targeted depression, with the BI as session 1 (Dep); 
and 
(d) 10 60-minute sessions of MI/CBT that addressed depression and alcohol use concurrently, 
with the BI as session 1 (Int). 
 
The SHADE project examined the efficacy of three psychological treatment conditions, 
delivered over a 10-week period, each with a 60-minute face-to-face BI as session 1.   These 
treatments were: 
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(a) 10 60-minute sessions of MI/CBT targeting depression and alcohol use concurrently, with 
the BI as session1 and delivered face-to-face with a trained Psychologist (Int); 
(b) 10 60-minute sessions of MI/CBT targeting depression and alcohol use concurrently, with 
the face-to-face BI as session 1, and ensuing sessions delivered by the SHADE computer 
program with weekly 15-minutes compliance checking face-to-face with a therapist 
(SHADE); and  
(c) 10 60-minute sessions of Person Centered Therapy (PCT), with the BI as session 1, 
delivered face-to-face by a trained Psychologist, and limited to supportive counseling 
techniques with no MI/CBT strategies. 
 
Across the SHADE and DAISI projects, the BI was identical in content and delivery mode, as was 
the 10-session integrated treatment program that used MI/CBT targeting both depression and 
alcohol use concurrently and was delivered face-to-face by a trained therapist. 
 
The protocols for the SHADE and DAISI projects were approved by a suitably constituted Ethics 
Committee of the institution within which the work was undertaken and conformed to the 
provisions of the Declaration of Helsinki (as revised in Tokyo 2004). 
 
Statistical Analysis 
Basic demographics were examined for the sample as a whole. 
 
All participants received a categorization according to the severity of their consumption of 
tobacco at baseline assessment.  The categories were based on previous research (Alati et al., 
2004; Shelef et al., 2009b) and included: non-smoker (0 cigarettes per day, cpd), light (1-9 cpd), 
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moderate (10-19 cpd) and heavy (20+ cpd).  The relationship between this new smoking 
variable and basic demographics was examined using oneway Analysis of Variance (ANOVA) 
for continuous variables and chi square analysis for categorical variables.   Relevant presenting 
symptoms (depression alcohol consumption, anxiety, cannabis use, general functioning) were 
also explored for associations with smoking category using oneway ANOVA, with Bonferroni 
posthoc analysis used to determine the nature of any differences in these variables according 
to smoking category. 
 
Hypothesis (a): that heavy smokers will have higher levels of depression and alcohol use than 
non-smokers 
Analysis of CoVariance (ANCOVA) compared the newly created smoking variable with BDI-II 
and OTI (alcohol) scores at baseline, with all baseline variables examined above that showed a 
significant relationship with smoking entered in as covariates.    
 
Hypothesis (b): that heavy smokers will have poorer outcomes on measures of depression and 
alcohol use than non-smokers. 
Two repeated measures ANOVAs examined the impact of smoking category (non-smoker, 
light, moderate, heavy) on treatment outcomes over time (one for depression and one for 
alcohol use).  No imputations for missing data were used, with participants providing data at 
each relevant timepoint included in the analysis.  Baseline, 3-, 6- and 12-month BDI-II and 
alcohol consumption scores were included in the model, and significant baseline variables as 
above were included as covariates in the analysis. 
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Hypothesis (c): that significant reductions in smoking tobacco will be observed from pre- to 
post-treatment and that these reductions will be moderated by treatment condition.   
Paired sampled t tests examined changes in tobacco consumption, based on OTI tobacco 
scores, between baseline and 3-months, baseline and 6-months and baseline and 12-months. 
 
Change scores were created for the primary outcome variables (BDI-II and OTI alcohol scores) 
and OTI tobacco scores at three, six and twelve months relative to baseline, to examine the 
relationship between smoking and treatment.  Positive scores on the change measures were 
indicative of decreases in tobacco, depression and alcohol use. Correlations were conducted 
between these variables to examine how changes in primary outcomes were associated with 
changes in smoking.   
 
Repeated measures ANOVA examined changes in OTI tobacco scores over time (baseline, 
three, six and twelve months) as a function of treatment allocation (BI, Dep, Alc, Int, Comp, 
PCT) at each timepoint.  No imputations for missing data were used, with participants 
providing data at each relevant timepoint included in the analysis.  Baseline variables with a 
significant relationship to smoking were included as covariates. 
 
RESULTS 
Demographics. 
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Of the 447 participants in the current study at baseline, 340 (76%) completed the 3-month 
follow-up assessment, 342 (77%) the 6-month and 315 (70%) the 12-month follow-up 
assessment.  Fifty eight percent (n=261) completed all three follow-up assessments. At 
baseline, 185 (41%) participants reported not smoking in the month prior to entry to the 
SHADE/DAISI studies, 63 (14%) were light smokers, 68 (15%) were moderate smokers and 131 
(29%) were heavy smokers of tobacco.  The mean age of the sample was 43.94 years (range 
18-73).  Sample characteristics are displayed in Table 1. 
 
Insert Table 1 about here 
 
Significant associations were found between levels of smoking at baseline and age and 
education.  Non-smokers were significantly older (age=47.13yrs) than were those who 
reported light (age=40.70, p<0.01), moderate (age=40.32, p<0.01) or heavy tobacco 
consumption (age=42.87, p<0.01).  Heavy smokers reported significantly less involvement in 
education compared to light smokers, having left secondary schooling at a younger age 
(age=15.93 vs. 16.63yrs respectively, p<0.01).  Non-smokers also left school at a significantly 
younger age than light smokers (age=16.09 vs.16.63, p=0.03).  A significantly higher proportion 
of males than females were classified as heavy smokers (63% vs. 37%, χ23=9.247, p=0.03).  A 
significantly higher proportion of participants with an Independent Depressive Disorder were 
non-smokers, relative to those with Substance-Induced Depression  (73% vs. 27%, χ23=8.385, 
p=0.04). Unemployed participants were significantly more likely to be light-heavy smokers 
(n=29-71, 47-55%) than non-smokers (n=42, 23%, p<0.01).  Participants currently receiving 
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government pensions were also significantly more likely to be light-heavy smokers (n=39-87, 
63-66%) than non-smokers (n=74, 40%, χ²3= 27.24, p<0.01). 
 
Associations between tobacco smoking and relevant presenting symptoms. 
As can be seen in Table 2, there were significant Bonferroni corrected associations between 
severity of smoking and cannabis use, anxiety and general functioning.   
 
Insert Table 2 about here 
 
Light and heavy smokers reported significantly higher levels of cannabis use at baseline than 
non-smokers.  Anxiety symptoms were significantly higher among moderate and heavy 
smokers compared to non-smokers.  Non-smokers displayed significantly higher levels of 
general functioning than moderate-heavy smokers. 
 
Hypothesis (a): that heavy smokers will report higher depression and alcohol consumption at 
baseline. 
ANCOVA compared BDI-II scores with smoking category, using age, gender, education, 
employment, primacy, mental health treatment, baseline cannabis use, baseline anxiety and 
baseline functioning as covariates. The ANOVA was not statistically significant (F(3,204)=0.935, 
p=0.425).  Significant covariates in the model were anxiety (p<0.01) and functioning (p<0.01). 
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The same ANCOVA model was used to examine the relationship between smoking category 
and alcohol consumption at baseline.  The model was statistically significant (F(3,205)=3.900, 
p=0.010), with simple contrast results indicating heavy smokers consumed significantly more 
alcohol than did non-smokers (M(non-smokers)=9.104 standard drinks per day, M(heavy 
smokers)=12.583 standard drinks per day, p=0.011).  None of the covariates was significant in 
the model. 
 
Hypothesis (b): that smokers will have poorer outcomes on measures of depression and alcohol 
use than non-smokers. 
Repeated measures MANOVA, using the covariates of age, gender, education, employment, 
pension receipt, mental health treatment, baseline cannabis use, baseline anxiety and baseline 
functioning, examined depression outcomes over time according to smoking categorization at 
baseline.  The MANOVA indicated a significant main effect of time on depression scores (F 
(3,182)=3.166, p=0.026), with post-baseline depression scores at 3-, 6- and 12-months being 
10.635, 11.656 and12.083 BDI-II points respectively lower than baseline.  However, the 
interaction between time, smoking status at baseline and depression was not statistically 
significant (F(9,184)=0.936, p=0.493).   
 
Using the same MANOVA model, there was no main effect of time on alcohol use 
(F(3,185)=1.470, p=0.224), and no significant interaction between alcohol use over time and 
smoking status at baseline (F(9,187)=0.401, p=0.935).  The significant covariate in this model 
was education (F(3,185)=2.891, p=0.037). 
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Hypothesis (c): that significant reductions in smoking tobacco will be observed from pre- to 
post-treatment, and that these reductions will be moderated by treatment condition. 
Paired sample t tests revealed that no significant changes in tobacco use (OTI tobacco scores) 
occurred between baseline and 3-month follow-up (M(baseline)=10.559, M(3-
months)=10.050, t=1.155, p=0.249, n=335), baseline and 6-months  (M(baseline)=10.731, M(6-
months)=10.594, t=0.255, p=0.799, n=338) and baseline and 12-month (M(baseline)=10.926, 
M(12-months)=10.846, t=0.087, p=0.931, n=310) follow-up assessments. 
 
Pearson correlations indicated a significant positive association between changes in smoking 
and changes in depression (r=0.14, p=0.01) between baseline and 3-months post-baseline 
assessments.  The same was true for changes in tobacco and changes in alcohol use over the 
same time period (r=0.15, p<0.01).  No significant relationships between changes in these 
three variables were found over the longer term. 
 
Repeated measures MANOVA, with the following covariates: age, gender, employment, 
education, pension receipt, mental health treatment, baseline cannabis use, baseline 
anxiety scores, and baseline functioning, examined changes in smoking between baseline, 
3-, 6- and 12-month follow-up according to treatment allocation.  The ANOVA indicated 
that the main effect of time on smoking was not statistically significant (F(3,151)=0.245, 
p=0.865).  None of the covariates was statistically significant, and the interaction between 
smoking over time and treatment allocation was not statistically significant 
(F(15,153)=1.714, p=0.135).  
 
  17 
Figure 1 displays the changes in tobacco use over time, according to treatment allocation, 
adjusted for the covariates in the model.   Participants in the integrated therapist condition 
reported a slight reduction of 1.53 cpd between baseline and 12-month follow-up assessment, 
as did those in the alcohol condition (1.49 cpd).  Those in the SHADE computer condition 
reported a 3.62-cpd reduction over the same time period.  No change in OTI tobacco scores 
was found for those in the BI (+0.34 cpd) and Dep (+0.54 cpd) conditions. Participants in the 
PCT condition reported a 1.16-cpd increase between baseline and 12-month follow-up 
assessments, with a peak increase observed at 6 months post-baseline (4.29 cpd).  
 
Insert Figure 1 about here 
 
DISCUSSION 
The aim of this study was to explore the impact of smoking tobacco on presenting symptoms 
and treatment outcomes for people enrolled in a trial of psychological treatment for comorbid 
depression and alcohol misuse.  Contrary to prediction, after controlling for important 
socioeconomic factors relevant to smoking, heavy smokers did not report elevated levels of 
depression compared to non-smokers, however they did drink significantly more alcohol (13 
versus 9 standard drinks per day).  Smoking status at baseline did not affect depression or 
alcohol use outcomes over the course of the study, and tobacco use was not significantly 
reduced as a function of treatment for depression and alcohol misuse.  These implications of 
these results are discussed in detail below. 
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Hypothesis (a): that heavy smokers will have higher levels of depression and alcohol use at 
baseline than will non-smokers. 
We did not find an association between increased severity of depression or alcohol use at 
baseline and tobacco use severity.  This may be due to the eligibility criteria of the study, with 
participants required to be experiencing at least moderate levels of depression and hazardous 
use of alcohol for the month prior to baseline, thus decreasing the variability of depression and 
alcohol use within the sample as a whole.  However, non-smokers generally reported lower 
levels anxiety, cannabis use and improved functioning compared to light, moderate and heavy 
smokers, and heavy smokers were significantly more likely to be unemployed, leave school at a 
younger age, and be receiving welfare payments.  Light smokers reported significantly better 
levels of functioning and lower alcohol consumption than did moderate and heavy smokers, 
and generally lower anxiety, somewhat indicative of a dose-response relationship between the 
amount of tobacco smoked and increased severity of symptoms.  This potentially illustrates 
the need for effective and evidence-based treatments options for smokers incorporating a 
wide range of intervention targets, and the potential harm reduction benefits of reduced 
tobacco smoking should this be a more realistic target.   
 
The relationship between anxiety and tobacco use is worthy of mention.  Our study found that 
moderate-heavy tobacco users at baseline reported significantly higher levels of somatization, 
anxiety and phobic anxiety than did their non-smoking counterparts.  Alati and colleagues 
(2004) found an association in their study between the experience of anxiety and tobacco use, 
however there was no evidence of a dose-response relationship, with anxiety levels not 
differing across light, moderate or heavy smokers. We did not find a statistically significant 
dose-response relationship between anxiety levels and severity of tobacco consumption (with 
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the exception of abstinence from tobacco being associated with significantly lower anxiety), 
however self-reported anxiety levels did increase as severity of smoking increased. This finding 
implies that anxiety may be an important target for treatment amongst smokers of any level of 
severity. 
 
As in the current study, previous studies have identified increased severity of smoking among 
males as compared to females (Grant, Hasin, Chou, Stinson, & Dawson, 2004). It has been 
suggested that the reward for smoking may be different between men and women, with 
women reporting more psychological rewards following smoking (e.g. relaxation) and men 
reporting more physiological rewards after smoking (Massak & Graham, 2008). Further, a 
range of socioeconomic variables, education, receiving welfare payments, and unemployment, 
were significantly associated with smoking severity at baseline.  Smoking was heavier in those 
with substance-induced depression than for people with independent depressive disorders, as 
well as those engaged with mental health treatment services in the 12 months prior to 
baseline.  These findings confirm the significance of smoking tobacco as not just a health, but 
also a social justice issue.  There are also implications for the opportunistic delivery of smoking 
cessation interventions, particularly for people engaged with both substance use and mental 
health services. 
 
Hypothesis (b): that heavy smokers will have poorer outcomes on measures of depression and 
alcohol use than non-smokers. 
Contrary to prediction, although depressive symptomatology did significantly improve over the 
12-month follow-up period, this was not moderated by baseline smoking levels.  Similarly, 
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alcohol use between baseline and 12-month follow-up was not significantly related to baseline 
smoking status.  There is little existing literature examining the impact of smoking levels on 
mental health or substance use treatment outcomes.  Research investigating the impact of 
varying degrees of alcohol use on smoking cessation programs revealed that moderate 
drinkers had poorer smoking cessation outcomes when compared to heavy drinkers (Kahler et 
al., 2008).  This was not the case in our study.  Although our results were not in line with the 
study hypotheses, it is reassuring to observe that heavy tobacco use does not interfere with 
treatment outcomes for both depression and alcohol misuse.  Our results did reveal, however, 
that reductions in tobacco use between baseline and three-month follow-up were significantly 
associated with reductions in depression and alcohol use over the same time period, 
suggesting that it is possible to make simultaneous changes on all three domains, at least in 
the short term.  Future studies should seek to address this association, and identify 
mechanisms by which the short-term changes could be maintained for longer-term benefit in 
all three domains (depression, alcohol and smoking).  Prolonged treatment may have been 
more successful in improving depression, alcohol and smoking, despite smoking not being 
specifically targeted in the treatment provided in the current study. Smoking may have been 
reduced further with additional targeted treatment and perhaps provision of nicotine 
replacement therapy. 
 
Hypothesis (c): that significant reductions in smoking tobacco will be observed from pre- to 
post-treatment and that these reductions will be moderated by treatment condition. 
It was anticipated that despite cigarette smoking not being directly targeted, the integrated 
approach to treatment taken in the current study might encourage generalization of skills to 
smoking behaviors, resulting in decreases in smoking.  However, there was no reduction in 
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smoking associated with treatment for depression or alcohol problems in the present study, 
indicating that tobacco use needs to be specifically targeted in treatment programs. 
 
Whilst the impact of depression and alcohol use treatment on smoking behavior has not been 
addressed in previous research, previous authors have reported that participants receiving 
treatment for smoking with skills that could be generalized to AOD use had poorer treatment 
outcomes compared to those who received the smoking cessation treatment alone (Burling, 
Burling, & Latini, 2001).  It was postulated that too much emphasis was given during treatment 
regarding the similarities of tobacco use and other substance abuse, which may have created 
undue pressure for the participants, who may have found these messages overwhelming. 
However, this was not the trend in our study.  Although not statistically significant, participants 
receiving an integrated CBT/MI treatment for depression and alcohol use, with arguably the 
greatest potential for generalization of skills, reported greater reductions in tobacco use 
between baseline and 12-month follow-up than did participants in other single-focused, non-
specific or brief treatments.  Those allocated to SHADE computer treatment reported the 
greatest reduction in cigarettes consumed per day of all the treatment groups.  We have 
previously reported that the SHADE computer program was associated with significantly 
increased client initiative in therapy, with responsibility for learning and using treatment 
strategies based largely within the client (Kay-Lambkin, Baker, Lewin, & Carr, 2011).  This may 
have also meant that the SHADE computer program had the largest potential for 
generalization of skills to other relevant areas of concern for the participant, including smoking 
tobacco.  Other research has demonstrated that a substance use-focused treatment was 
effective in reducing tobacco use among adolescents (Shelef et al., 2009a).  The authors 
suggested that this might be due to the targeting of external cues in the substance use 
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treatment, which were easily generalized by participants to their smoking behaviors.  This may 
also explain the finding in the current study, that participants receiving alcohol-focused 
treatment made reductions of a similar magnitude to the integrated therapist-delivered 
CBT/MI in relation to cigarettes per day.  Importantly, some exposure to CBT/MI strategies, 
regardless of focus, is important in the context of tobacco use among people with depression 
and alcohol use problems, with participants in the PCT condition (non-directive supportive 
counseling, with no CBT/MI strategies offered) reporting increases in tobacco use over the 
study period. 
 
 
Limitations 
 
A number of sample and methodological limitations are important to note. Given the sample 
was seeking treatment for depression and alcohol use problems, they may not represent the 
wider population with comorbid depression and alcohol use problems. The sample involved in 
this research was generally of Caucasian background and the findings may not be generalizable 
to other cultural groups.  With regards to substance use, current usage may have been under-
reported, and no biological verification was included to confirm smoking abstinence.  We only 
measured smoking prospectively from baseline, and not retrospectively.  Hence, we do not 
know how recently the non-smokers in our sample had stopped smoking, or for how long 
current smoking levels had been maintained by participants.  Given this study was a secondary 
data analysis of existing datasets that did not focus on tobacco use, key smoking outcome data 
was also not collected (e.g. quit attempts).   
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Future Directions 
Notwithstanding the above limitations, the present research is amongst the first to investigate 
the possible relationship between levels of tobacco smoking and the severity of symptoms 
experienced in a comorbid adult population presenting for treatment for depression and 
alcohol problems.  
 
These results have important implications for the assessment and treatment of clients within 
Mental Health services, Drug and Alcohol facilities and the general health care system.  To 
effectively treat individuals with tobacco use and other comorbid disorders, we need to have a 
detailed understanding of the influence smoking has on the person’s psychological, biological 
and social existence.  By understanding these associations, offering comprehensive 
assessments around these issues, and broadening the scope of mental health and AOD 
treatments to include functional improvement, perhaps in the form of vocational and other life 
skills training, we may be able to make significant inroads into these pressing health concerns.  
 
The issue of the generalisability of skills learned in therapy to secondary problems remains an 
interesting area of discussion, and is particularly relevant to the comorbidity literature. The 
idea of developing treatments that target multiple conditions is also interesting to explore. The 
question of whether smoking is targeted within treatments for mental health or AOD use 
disorders raises questions about individuals becoming overwhelmed during the interventions 
and compromising the effectiveness of the initial treatment focus. Alternatively, acting 
opportunistically to target smoking has its own difficulties, including the current barriers to 
identifying tobacco smoking as important in the context of other (possibly more immediate) 
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health concerns. Furthermore, targeting functional improvement in individuals experiencing 
comorbidities in mental health and AOD use such as vocational skills and life skills training also 
warrants further investigation in regards to effectiveness. 
 
Clearly we need to focus more on the area of smoking and comorbidity, given the huge public 
health impact of smoking on the global community.  Tobacco smoking is the single most 
preventable cause of disease and death worldwide. Current hindrances to maintaining strong 
declines in smoking rates are in part related to the reach, effectiveness and adoption of 
smoking cessation support. Increasing the proportion of smokers attempting to quit, together 
with increasing the proportion using effective strategies on those quit attempts, will add 
downward pressure to smoking rates.   
 
ACKNOWLEDGEMENTS 
The DAISI project was funded by the National Health and Medical Research Council of 
Australia.  The SHADE study was funded by the Alcohol Education and Rehabilitation 
Foundation. 
 
REFERENCES 
ABS. (2006). Tobacco smoking in Australia: a snapshot 2004-05. Canberra: Australian 
Bureau of Statistics.  Available at: http://www.abs.gov.au  
AIHW. (2008). Australia's Health 2008. Canberra: Australian Institute of Health and 
Welfare (AIHW Cat No. AUS 73). 
Alati, R., Kinner, S., Najman, J.M., Fowler, G., Watt, K., & Green, D. (2004). Gender 
differences in the relationships between alcohol, tobacco and mental health in 
patients attending an emergency department. Alcohol & Alcoholism, 39(5), 463-
469.  
APA. (1994). Global assessment of functioning scale Diagnostic and Statistical Manual, 
Fourth Edition. Washington: American Psychiatric Association. 
  25 
APA. (1995). Practice guideline for the treatment of patients with substance use 
disorders: Alcohol, cocaine, opiods. American Journal of Psychiatry, 152(11 
Supplement), 1-59.  
APA. (1996). Practice guidelines for the treatment of patients with nicotine dependence. 
American Journal of Psychiatry, 153(10), S1-S31.  
APA. (2000). Practice guideline for the treatment of patients with major depressive 
disorder (Revision). American Journal of Psychiatry, 157(4 Suppl), 1-45.  
Baker, A., Richmond, R., Haile, M., Lewin, T.J., Carr, V.J., Taylor, R., . . . Wilhelm, K. (2006). 
A randomized controlled trial of a smoking cessation intervention among people 
with a psychotic disorder. American Journal of Psychiatry, 163, 1934-1942.  
Baker, A.L., Ivers, R., Bowman, J., Butler, T., Kay-Lambkin, F., Wye, P., . . . Wodak, A. 
(2006). Where there's smoke, there's fire: high prevalence of smoking among 
some sub-populations and recommendations for intervention. Drug and Alcohol 
Review, 25(1), 85-96.  
Baker, A.L., Kavanagh, D., Kay-Lambkin, F., Hunt, S., Lewin, T.J., Carr, V.J., & Connolly, J. 
(2010). Randomised controlled trial of CBT for co-existing depression and alcohol 
problems: Short-term outcome. Addiction, 105 87-99.  
Beck, A.T., Steer, R.A., & Brown, G.K. (1996). The Beck Depression Inventory, Second 
Edition: Manual. San Antonio: The Psychological Corporation. 
Burling, T., Burling, A. , & Latini, D. . (2001). A controlled smoking cessation trial for 
substance dependent inpatients. Journal of Consulting and Clinical Psychology, 
69(2), 295-304.  
Cargill, B., Emmons, K., Kahler, C., & Brown, R. . (2001). Relationship among alcohol use, 
depression, smoking behaviour, and motivation to quit smoking with hospitalised 
smokers. Psychologiy of Addictive Behaviors, 15(3), 272-275.  
Cooney, N., Litt, M., Cooney, J., Pilkey, D., Steinberg, H., & Oncken, C. . (2007). Concurrent 
brief versus intensive smoking intervention during alcohol dependence treatment. 
Psychology of Addictive Behaviors, 21(4), 570-575.  
Darke, S., Hall, W., Wodak, A., Heather, N., & Ward, J. (1992). Development and validation 
of a multi-dimensional instrument for assessing outcome of treatment among 
opiate users: the Opiate Treatment Index. British Journal of Addiction, 87, 733-
742.  
Derogatis, L.R., & Melisaratos, N. (1983). The brief symptom inventory: An introductory 
report. Psychological Medicine, 13, 595-605.  
Dunn, K., Sigmon, S., Reimann, E., Badger, G., Heil, S., & Higgins, S. . (2010). A 
contingency-management intervention to promote initial smoking cessation 
among opioid-maintained patients. Experimental and Clinical 
Psychopharmacology, 18(1), 37-50.  
First, M.B., Spitzer, R.L., Gibbon, M., & Williams, J.B.W. (2001). (2001). Structured Clinical 
Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New 
York. 
Grant, B., Hasin, B., Chou, P., Stinson, F., & Dawson, D. (2004). Nicotine dependence and 
psychiatric disorders in the United States: results from the National 
Epidemiological Survey on Alcohol and Related Conditions. Archives of General 
Psychiatry, 61, 1107-1115.  
Hitsman, B., Abrams, D., Shadel, W., Niaura, R., Borrelli, B., & Emmons, K. . (2002). 
Depressive symptoms and readiness to quit smoking among cigarette smokers in 
outpatient alcohol treatment. Psychology of Addictive Behaviors, 16(3), 264-268.  
  26 
Jane-Llopis, E., & Matytsina, I. . (2006). Mental health and alcohol, drugs and tobacco: a 
review of the comorbidity between mental disorders and the use of alcohol, 
tobacco and illicit drugs. Drug and Alcohol Review, 25, 515-536.  
Kahler, C., Metrik, J., LaChance, H., Ramsey, S., Abrams, D., & Monti, P. (2008). Addressing 
heavy drinking in smoking cessation treatment: A randomised clinical trial. Journal 
of Consulting and Clinical Psychology, 76(5), 852-862.  
Kalman, D., Kim, S., DiGirolamo, G., Smelson, D. , & Ziedoni, D. . (2010). Addressing 
tobacco use disorder in smokers in early remission from alcohol dependence: the 
case for integrating smoking cessation services in substance use disorder 
treatment programs. Clinical Psychology Review, 30(12-24).  
Kay-Lambkin, F., Baker, A., Kelly, B., & Lewin, T.J. (2011). Clinician-assisted computerised 
versus therapist-delivered treatment for depressive and addictive disorders: 
results of a randomised controlled trial. Medical Journal of Australia, 195, S44-
S50.  
Kay-Lambkin, F., Baker, A.L., Lewin, T.J., & Carr, V.J. (2011). Acceptability of a clinician-
assisted computerized psychological intervention for comorbid mental health and 
substance use problems: Treatment adherence data from a randomized controlled 
trial. Journal of Medical Internet Research, 13(1), e11p11-e11p11.  
Massak, A., & Graham, K. (2008). Is the smoking-depression relationship confounded by 
alcohol consumption? An analysis by gender. Nicotine and Tobacco Research, 
10(7), 1231-1243.  
NHMRC. (2009). Australian guidelines to reduce health risks from drinking alcohol. 
Canberra: National Health and Medical Research Council of Australia ISBN Online: 
1864963808 (available at http://www.ag.gov.au/cca). 
Shelef, K., Diamond, G., Diamond, G., & Myers, M. . (2009a). Changes in tobacco use 
among adolescent smokers in substance abuse treatment. Psychology of Addictive 
Behaviors, 23(2), 355-361.  
Shelef, K., Diamond, G.S., Diamond, G.M., & Myers, M. . (2009b). Changes in tobacco use 
among adolescent smokers in substance use treatment. Psychology of Addictive 
Behaviors, 23(2), 355-361.  
Wilhelm, K. , Mitchell, P. , Slade, T., Brownhill, S., & Andrews, G. (2003). Prevalence and 
correlates of DSM-IV major depression in an Australian national survey. Journal of 
Affective Disorders, 75, 155–162.  
Wilhelm, K., Wedgewood, L., Niven, H., & Kay-Lambkin, F.J. (2006). Smoking cessation and 
depression: Current knowledge and future directions. Drug and Alcohol Review, 
25(1), 97-107.  
 
 
 
 
  27 
Table 1: Characteristics of the study sample 
 N % 
Gender 
Males 
Females 
 
234 
213 
 
53 
47 
Marital Status 
Single, never married 
Divorced/Separated/Widowed 
Married/Defacto 
 
130 
168 
149 
 
29 
38 
33 
Completed secondary school 178 40 
Unemployed 174 39 
Receiving Welfare 243 54 
Primacy 
Independent Depression 
Alcohol-induced Depression 
Unable to determine 
 
184 
107 
156 
 
41 
24 
35 
12-month Diagnosis 
Major Depressive Disorder 
Alcohol Dependence 
 
276 
361 
 
62 
81 
Treatment Allocation 
Brief Intervention 
Depression-focused 
Alcohol-focused 
Integrated-focused 
SHADE 
Person-centered Therapy 
 
70 
71 
68 
133 
56 
54 
 
16 
16 
15 
29 
12 
12 
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Table 2: Levels of depression, alcohol consumption and other domains as a function of severity 
of tobacco consumption at baseline assessment. Note: Non-smokers=0 cigarettes per day 
(cpd), Light=1-9 cpd, Moderate=10-19 cpd and Heavy=20+ cpd. 
Severity of Smoking N Mean SD1 Sig. 
BDI-II2 depression 
Non-smokers 
Light 
Moderate 
Heavy 
 
185 
63 
67 
130 
 
30.48 
32.38 
32.78 
32.02 
 
8.83 
8.49 
9.64 
8.74 
 
 
n.s. 
OTI3-alcohol 
Non-smokers 
Light 
Moderate 
Heavy 
 
185 
63 
68 
131 
 
9.93 
9.13 
11.06 
11.33 
 
7.81 
7.08 
9.69 
7.74 
 
 
n.s. 
OTI3-Cannabis 
Non-smokers 
Light 
Moderate 
Heavy 
 
184 
62 
67 
129 
 
0.29 
3.14 
2.14 
2.61 
 
2.37 
9.78 
5.23 
7.56 
 
 
Non<Light, p<0.01 
 
Non<Heavy, p<0.01 
BSI4 – somatization 
Non-smokers 
Light 
Moderate 
Heavy 
 
154 
57 
59 
108 
 
1.00 
1.28 
1.42 
1.49 
 
0.82 
0.84 
0.82 
0.75 
 
 
 
Mod>Non, p<0.01 
Heavy>Non, p<0.01 
BSI4 - anxiety 
Non-smokers 
Light 
Moderate 
Heavy 
 
154 
57 
59 
108 
 
1.48 
1.70 
1.92 
1.90 
 
1.01 
0.93 
1.09 
0.89 
 
 
 
Mod>Non, p<0.05 
Heavy>Non, p<0.01 
BSI4 – phobic anxiety 
Non-smokers 
Light 
Moderate 
Heavy 
 
154 
57 
59 
108 
 
0.86 
1.20 
1.37 
1.27 
 
1.00 
1.08 
1.24 
1.08 
 
 
 
Mod>Non, p<0.01 
Heavy>Non, p<0.01 
GAF5 - functioning 
Non-smokers 
Light 
Moderate 
Heavy 
  
167 
59 
64 
121 
 
58.78 
57.42 
54.03 
53.311 
 
9.00 
10.00 
10.79 
11.56 
 
 
 
Non>Mod, p<0.01 
Non>Heavy, p<0.01 
1 Standard Deviation 
2 Beck Depression Inventory II scores 
3 Opiate Treatment Index Scores representing average use occasions per day 
4 Brief Symptom Inventory Scores 
5 Global Assessment of Functioning scores 
